Compare · ABC vs SCNX
ABC vs SCNX
Side-by-side comparison of AmerisourceBergen Corporation (ABC) and Scienture Holdings Inc. (SCNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABC and SCNX operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- ABC is the larger of the two at $28.47B, about 1946.6x SCNX ($14.6M).
- SCNX has hit the wire 5 times in the past 4 weeks while ABC has been quiet.
- ABC has more recent analyst coverage (17 ratings vs 0 for SCNX).
- Company
- AmerisourceBergen Corporation
- Scienture Holdings Inc.
- Price
- $179.95-0.32%
- $0.36+0.36%
- Market cap
- $28.47B
- $14.6M
- 1M return
- -
- -14.20%
- 1Y return
- -
- -65.54%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 0
- 5
- Recent ratings
- 17
- 0
AmerisourceBergen Corporation
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; offers specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets, as well as provides demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Conshohocken, Pennsylvania.
Latest ABC
- Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors
- Clark Gina sold $253,528 worth of shares (1,100 units at $230.48), decreasing direct ownership by 4% to 24,802 units (SEC Form 4)
- SEC Form SC 13G filed by AmerisourceBergen Corporation
- SEC Form SC 13G/A filed by AmerisourceBergen Corporation (Amendment)
- AmerisourceBergen Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- AmerisourceBergen Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- SEC Form FWP filed by AmerisourceBergen Corporation
- Nally Dennis M was granted 132 shares, increasing direct ownership by 1% to 9,383 units (SEC Form 4)
- Baumann Werner was granted 106 shares, increasing direct ownership by 17% to 720 units (SEC Form 4)
- Tyler Lauren M was granted 106 shares, increasing direct ownership by 17% to 720 units (SEC Form 4)
Latest SCNX
- SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
- SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
- Scienture Holdings Inc. filed SEC Form 8-K: Leadership Update
- Scienture Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
- SEC Form 10-Q filed by Scienture Holdings Inc.
- Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
- SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
- Scienture Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Scienture Holdings Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits